Clostridioides difficile infection is a major healthcare-associated infection, causing significant morbidity and mortality, ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

The team developed the treatment for Clostridioides difficile ... of new probiotic strategies for humans to treat C.

In this randomized controlled trial, among hospitalized patients with a bloodstream infection, seven days of antibiotic ...

A synthetic microbiome therapy, tested in mice, holds promise as a new treatment for C. difficile, a notoriously difficult-to-treat bacterial infection, according to a team of researchers.

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

Researchers from Penn State University have developed a novel synthetic microbiome therapy for Clostridioides difficile (C. difficile), a bacterium that can cause severe diarrhea, abdominal pain and ...

The team developed the treatment for Clostridioides difficile ... of new probiotic strategies for humans to treat C. difficile infections as an alternative to antibiotics and conventional fecal ...

The pathogen C. diff—the most common cause of health care-associated infectious diarrhea—can use a compound that kills the ...